Meke Innovation

Meke Innovation is a biotechnology company based in Beijing, China, specializing in the development of next-generation vaccines using mRNA and recombinant protein technologies. The company gained prominence for its rapid development of COVID-19 vaccine candidates, leveraging a proprietary mRNA platform designed for high immunogenicity and stability. Meke Innovation collaborates closely with academic institutions, including the Chinese Academy of Sciences, to advance its pipeline of infectious disease preventatives. Its business model focuses on the integration of cutting-edge molecular biology with scalable manufacturing processes to address global health challenges. The company is currently advancing several candidates through clinical trials, aiming to provide effective solutions for emerging viral threats.